Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients

Terapevticheskii Arkhiv

Volumn 72, Issue 8, 2000, Pages 50-54

  Sjostrom, L ^a   Rissanen, A ^a   Andersen, T ^a   Boldrin, M ^a   Golay, A ^a   Koppeschaar, H ^a   Krempf, M ^a  

^a NONE

Author keywords

Controlled study; Obesity; Orlistat; Treatment

Indexed keywords

ANTIOBESITY AGENT; BIOLOGICAL MARKER; CHOLESTEROL; LACTONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE;

ADOLESCENT; ARTICLE; BLOOD; BODY MASS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; LOW FAT DIET; MALE; MULTICENTER STUDY; OBESITY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; WEIGHT GAIN;

ADOLESCENT; ANTI-OBESITY AGENTS; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, LDL; DIET, FAT-RESTRICTED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTONES; LIPASE; MALE; OBESITY; RECURRENCE; WEIGHT GAIN;

EID: 0033647554     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Foreyt J., Goodrick K. Lancet. 1995; 346: 34-35.
2. Nutrition and physical activity task force. Department of Health. London: HMSO, 1995.
3. Prescott-Clark P., Primatesta P. Health survey for England. 1995. Department of Health. London: HMSO, 1997.
4. Kuczmarski R. J., Flegal K. M., Campbell S. M., Jonson C. L. J. A. M. A. 1994; 272: 205-211.
5. Kukowa-Wolk A., Bergström R. J. Epidemiol. Commun. Hlth. 1993; 47: 195-199.
6. Seidell J. C. Horm. Metab. Res. 1997; 29: 155-158.
7. SIGN. Obesity in Scotland: integrating prevention with weight management. A National Clinical Guideline recommended for use in Scotland by the Scottish Intercollegiate Guidelines Network. Pilot edition, November, 1996. Edinburg, 1996.
8. Goldstein D. J. Int. J. Obes. 1992; 6: 397-415.
9. National Task Force on the Prevention and Treatment of Obesity. Long term pharmacotherapy in the management of obesity. J. A. M. A. 1996; 276: 1907-1915.
10. Lissner L., Heitmann B. L. Eur. J. Clin. Nutr. 1995; 49: 79-90.
11. Golay A., Bobbioni E. Int. J. Obes. 1997; 21 (suppl): S2-11.
12. Zhi J., Melia A. T., Guerciolini R. et al. Clin. Pharmacol. Ther. 1994; 56: 82-85.
13. James W. P. T., Schofield E. C. Human energy requirements: a manual for planners and nutritionalists. Published by arrangement with the Food and Agriculture Organization of the Unit- ed Nations. Oxford: Oxford University Press. 1990.
14. Krotkiewski M., Sjoestroem L., Bjoerntorp P. et al. Int. J. Obes. 1977; 1: 395-416.
15. Drent M. L., van der Veen E. A. Int. J. Obes. Ibid. 1993; 17: 241-244.
16. Drent M. L., Larsson I., William-Olsson T. et al. Int. J. Obes. Ibid. 1995;19: 221-226.
17. Hauptman J. B., Jeunet F. S., Hartmann D. Am. J. Clin. Nutr. 1992; 55: 309S-313S.
18. Tonstad S., Pometta D., Erkelens D. W. et al. Eur. J. Clin. Pharmacol. 1994; 46; 405-410.
19. Sjoestroem C. D., Lissner L., Sjoestrom L. Obes. Res. 1997; 5: 519-530.
20. Guy-Grand B., Apfelbaum M., Crepaldi G. et al. Lancet. 1989:1: 1142-1145.
21. Editorial. Diet pills Redux. N. Engl. J. Med. 1997; 337: 629-630.
22. Melia A. T., Koss-Twardy S. G., Zhi J. J. Clin. Pharmacol. 1996; 36: 647-653.
23. Zhi J., Melia A. T., Koss-Twardy S. G. et al. J. Clin. Pharmacol. Ibid. P. 152-159.